Payment overview · 2025
General Payments
$143.11
8 reported records · 6 companies
Healthcare provider profile · identity verified
Timothy A Viator, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEW IBERIA, LA · NPI 1659369916
Verified facts
What the public records show
CMS Open Payments records show Timothy A Viator, M.D. received $143.11 in general payments during 2025 across 8 reported records.
MILLICENT US INC accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MILLICENT US INC | Unresolved — no canonical attribution shown | $40.07 | 28.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.05 | 19.6% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $24.55 | 17.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.43 | 13.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.28 | 11.4% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $14.73 | 10.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $143.11 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.05 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.05 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| FEMLYV Normalized: femlyv |
Drug | MILLICENT US INC | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| INTRAROSA Normalized: intrarosa |
Drug | MILLICENT US INC | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 204 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
204 | 47 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1126 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 817 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 809 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 784 | 146 |
| Gabapentin | Gabapentin | 673 | 112 |
| Eliquis | Apixaban | 562 | 51 |
| Metformin Hcl | Metformin Hcl | 546 | 120 |
| Sertraline Hcl | Sertraline Hcl | 524 | 109 |
| Omeprazole | Omeprazole | 494 | 115 |
| Lisinopril | Lisinopril | 473 | 97 |
| Furosemide | Furosemide | 456 | 72 |
| Potassium Chloride | Potassium Chloride | 409 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 403 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 391 | 93 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 378 | 55 |
| Simvastatin | Simvastatin | 376 | 60 |
| Trazodone Hcl | Trazodone Hcl | 374 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 351 | 92 |
| Donepezil Hcl | Donepezil Hcl | 348 | 37 |
| Alprazolam | Alprazolam | 347 | 59 |
| Buspirone Hcl | Buspirone Hcl | 341 | 44 |
| Montelukast Sodium | Montelukast Sodium | 310 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 69 |
| Losartan Potassium | Losartan Potassium | 282 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 262 | 45 |
| Carvedilol | Carvedilol | 251 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 242 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 239 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 233 | 30 |
| Memantine Hcl | Memantine Hcl | 228 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 227 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 208 | 34 |
| Ozempic | Semaglutide | 204 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 198 | 29 |
| Mirtazapine | Mirtazapine | 195 | 25 |
| Levetiracetam | Levetiracetam | 194 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 22 |
| Glipizide | Glipizide | 181 | 39 |
| Allopurinol | Allopurinol | 180 | 23 |
| Meloxicam | Meloxicam | 177 | 40 |
| Tramadol Hcl | Tramadol Hcl | 177 | 38 |
| Tradjenta | Linagliptin | 173 | 15 |
| Finasteride | Finasteride | 145 | 17 |
| Lovastatin | Lovastatin | 143 | 40 |
| Sucralfate | Sucralfate | 138 | 23 |
| Spironolactone | Spironolactone | 136 | 22 |
| Bupropion Xl | Bupropion Hcl | 135 | 39 |
| Entresto | Sacubitril/Valsartan | 126 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 41 |
| Lorazepam | Lorazepam | 121 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 20 |
| Farxiga | Dapagliflozin Propanediol | 117 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 112 | 25 |
| Olanzapine | Olanzapine | 110 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 19 |
| Xarelto | Rivaroxaban | 103 | 13 |
| Clonazepam | Clonazepam | 99 | 17 |
| Prednisone | Prednisone | 96 | 62 |
| Alendronate Sodium | Alendronate Sodium | 94 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 94 | 76 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 28 |
| Famotidine | Famotidine | 89 | 22 |
| Latanoprost | Latanoprost | 88 | 13 |
| Risperidone | Risperidone | 87 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 85 | 24 |
| Atenolol | Atenolol | 84 | 15 |
| Aripiprazole | Aripiprazole | 83 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 32 |
| Mounjaro | Tirzepatide | 77 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | suppressed |
| Baclofen | Baclofen | 76 | 14 |
| Divalproex Sodium | Divalproex Sodium | 73 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 44 |
| Januvia | Sitagliptin Phosphate | 72 | 18 |
| Jardiance | Empagliflozin | 69 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Myrbetriq | Mirabegron | 68 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 67 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 29 |
| Ezetimibe | Ezetimibe | 66 | 14 |
| Nifedipine Er | Nifedipine | 64 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 64 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 17 |
| Methimazole | Methimazole | 61 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 39 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 55 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 13 |
| Rivastigmine | Rivastigmine Tartrate | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 49 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 13 |
| Metformin Hcl Er | Metformin Hcl | 47 | 14 |
| Oxcarbazepine | Oxcarbazepine | 46 | suppressed |
| Trulicity | Dulaglutide | 46 | suppressed |
| Anastrozole | Anastrozole | 45 | suppressed |
| Digoxin | Digoxin | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 42 | 17 |
| Synthroid | Levothyroxine Sodium | 42 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 38 |
| Clonidine Hcl | Clonidine Hcl | 39 | 15 |
| Lactulose | Lactulose | 39 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 39 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 34 |
| Mupirocin | Mupirocin | 37 | 22 |
| Nystatin | Nystatin | 37 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | 11 |
| Ketoconazole | Ketoconazole | 36 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Calcitriol | Calcitriol | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Gemtesa | Vibegron | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 27 |
| Valacyclovir | Valacyclovir Hcl | 30 | 14 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 29 | suppressed |
| Estradiol | Estradiol | 29 | 11 |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 25 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | 11 |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Humulin R | Insulin Regular, Human | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Perphenazine | Perphenazine | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Paliperidone Er | Paliperidone | 18 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 18 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 16 | 14 |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $143.11 · 8 records | MILLICENT US INC | CRYSVITA, FEMLYV, INTRAROSA, MOUNJARO, MYFEMBREE, Ozempic, Rybelsus, SLYND, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error